mate, this stock is exposed mainly in US market, Lifting restriction in AU does not have marterialy impact on revenue, we have like few hospitals using VHT platform. The majority is in US
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%